Literature DB >> 2422937

The tumor marker CA 125 is a common constituent of normal cervical mucus.

H W de Bruijn, T van Beeck Calkoen-Carpay, S Jager, J M Duk, J G Aalders, G J Fleuren.   

Abstract

The presence of the tumor marker CA 125 was studied in the cervices of healthy women. Immunohistochemical staining of normal cervical tissue demonstrated the presence of CA 125 in the tall columnar cells of the endocervical epithelium but not in the ectocervical squamous epithelium. We measured very high levels of CA 125 in liquefied cervical mucus from women with regular menstrual cycles. At midcycle, levels ranged from 14,200 to 153,000 U/ml (n = 13) in cervical mucus, while normal levels less than 35 U/ml were found in the corresponding serum samples. Levels of CA 125 in cervical mucus are comparable to the high levels found in cyst fluids from ovarian tumors (median 24,600 U/ml, n = 25). When secretion of cervical mucus was stimulated by ethinyl estradiol, equally high levels were found (7900 to 138,000 U/ml, n = 10). We conclude that the tumor marker CA 125 is synthesized and secreted by normal endocervical cells. Apparently an effective barrier exists between the endocervical mucosa and the circulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422937     DOI: 10.1016/0002-9378(86)90757-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

1.  CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and fallopian tube. I. Immunohistochemical detection.

Authors:  A Scharl; G Crombach; M Vierbuchen; H Müsch; A Bolte
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

2.  CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and Fallopian tube. II. Immunoradiometric determination in secretions, tissue extracts and serum.

Authors:  G Crombach; A Scharl; H Würz
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

3.  CA 125 and CA 19-9 in peritoneal, cyst and amniotic fluids.

Authors:  P Inaudi; L Pasqui; G C Torre; F M Severi; G Centini; W Gioffré; S Danero; N D'Antona
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

4.  Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies.

Authors:  A M Paoletti; G G Serra; V Mais; S Ajossa; S Guerriero; M Orrù; G B Melis
Journal:  J Assist Reprod Genet       Date:  1995-04       Impact factor: 3.412

5.  Purification and immunochemical characterization of ascitic fluid glycoproteins containing certain tumor-associated and blood group antigen markers.

Authors:  M Venegas; L Liu; L Lovell; L E Davis; B Anderson; T Wilbanks; M Hass; G Manderino; H Rittenhouse
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

6.  Immunohistological characterization of a monoclonal antibody (OV632) against epithelial ovarian carcinomas.

Authors:  G J Fleuren; E G Coerkamp; M Nap; L J vd Broek; S O Warnaar
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

7.  Relationship between serum CA 125 levels, endometrial thickness and corpus luteum function in different stages of ovarian activity.

Authors:  G Ozakşit; N O Turhan; H Oral; N Doğu; O Gökmen
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

8.  Immunoreactive determinants of CA 125 in women with endometriosis.

Authors:  O A Mojiminiyi; M E Bramwell; S H Kennedy; B J Shepstone; S M Humm; D H Barlow
Journal:  J Clin Pathol       Date:  1989-12       Impact factor: 3.411

9.  Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer.

Authors:  Shu-Ming He; Fuqi Xing; Hong Sui; Youming Wu; Yongli Wang; Dong Wang; Guanghui Chen; Zijing Kong; Shu-Feng Zhou
Journal:  Med Sci Monit       Date:  2011-11

10.  Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.

Authors:  H Halila; M L Huhtala; C Haglund; S Nordling; U H Stenman
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.